Dialogue Health Technologies Inc.
DLHTF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.00 | -0.21 | -1.19 |
| FCF Yield | -8.64% | -10.65% | -7.36% | -5.08% |
| EV / EBITDA | -5.84 | -0.50 | -12.96 | -22.56 |
| Quality | ||||
| ROIC | -25.43% | -21.28% | -35.16% | -36.80% |
| Gross Margin | 49.75% | 42.33% | 40.20% | 54.37% |
| Cash Conversion Ratio | 0.60 | 0.09 | 0.91 | 1.08 |
| Growth | ||||
| Revenue 3-Year CAGR | 34.51% | 88.94% | 107.40% | 2,160,689.96% |
| Free Cash Flow Growth | 33.28% | -24.09% | -42.44% | -29.51% |
| Safety | ||||
| Net Debt / EBITDA | 2.86 | 0.41 | 2.23 | 1.93 |
| Interest Coverage | -227.81 | -131.92 | -40.00 | -48.46 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 48.76 | 48.48 | 74.05 | 75.80 |